· Oral ALK&EGFR dual-target inhibitor for advanced NSCLC

· ALK: Wild Type, C1156Y, G1202R, L1196M point mutation

· EGFR: Exon 19 deletion, L858R, C797S mutations

· NSCLC patients with disease progression after previous ALK or EGFR TKI treatment

*Previous treatment:
- ALK: alectinib, brigatinib, crizotinib, ceritinib
- EGFR: erlotinib, gefitinib, afatinib, dacomitinib, osimertinib, Lazertinib

· Potential for expansion into other indications

· ALK: Superior effectiveness compared to lorlatinib (potential alternative)

· EGFR: Effective for sensitizing, double, and triple mutations  overcomes osimertinib resistance

· Orally administered small-molecule compound with high bioavailability and tolerable levels of toxicity in non-clinical studies

· Relatively simple manufacturing process  low cost of goods

· Well-documented patent portfolio (Derived from TOFPOMICS)

· Patent registered in Republic of Korea, Japan, China, United States of America, Russia, Brazil, Australia, Canda

· Patent application filed in Europe